[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2017/04/Entra.jpg” thumb_width=”150″ /]Entra is a London startup company developing a quick, home-based blood test for clinically valid blood counts. Targeted to the needs of chemotherapy patients, where blood counts are critical in their receiving and timing of treatments, the Affinity (photo left) is designed to take a small sample, analyze it, wirelessly send the information to the hospital or clinic, and enter into the patient’s EHR. It is currently being tested with The Royal Marsden Hospital, a leading UK cancer center, to validate its optical analytics and generate cost-effectiveness data. Blood counts are not only critical to correct patient treatment, but also to assigning and canceling appointments. Entra is being supported by £1.14 million in funding from Innovate UK, much of it through the Biomedical Catalyst. The timeline to commercial release is being estimated at two years. It’s anticipated that once verified, the blood count technology could be further developed for other uses. Gov.UK. Hat tip to our Eye on Tenders, Susanne Woodman
Raising funds for another type of blood testing is a NYC-based biotech company, Haystack, which is pioneering a single blood test for multiple cancers through proteome molecular profiling. Its goal is early detection of multiple cancers through one test using panels of biomarkers. The research team headed by John Wilson, PhD, who is affiliated with Cold Spring Harbor Laboratory, are ready first with pancreatic and lung cancer samples. This has gained the interest of pharma companies who are seeking a companion diagnostic for their drug trials. It was also a category winner at MedStartr’s #MedMo16 last December and presenter at #RISE2017 in March. Haystack’s MedStartr page. Video of Haystack’s presentation at #RISE2017 is on YouTube here (at 58:00) TTA is a MedStartr and Health 2.0 NYC supporter/media sponsor since 2010; event videos are available at Medstartr.tv.
[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2015/11/MedStartr_red_grey_sm.jpg” thumb_width=”125″ /]Having attended two conferences in the past two weeks, and squinting to read the tea leaves in the cup, there are some trends that this Editor is picking up. They are quite different from what has been seen over the past year or two. They’ll be expanded on in articles to follow. From the top:
- Successful companies fit into a bigger picture. Startups into early-stage companies, which were the focus at #MedMo16, are now playing the niches like genetics, patient-focused discovery, condition management and cost-effective specialized clinical innovations.
- Anything that simplifies a process and saves money is attractive. Complex ‘big data’, analytics and ‘population health/integration’ solutions aren’t in the lead anymore because there are a lot of them and they all look alike.
- Nothing is revolutionary. The idea that an app, device or software will ‘revolutionize healthcare as we know it’ is now recognized as absurd. (The cocktail/drinks party is ovah!) Cases must be proved first, usually on your self-funded or FFF (families, friends and fools) dime, if you want to partner with the Big Dogs.
- Value-based care, this year’s darling, is already being seen as a vague ‘catch-all’ in a way that Triple Aim and ‘outcomes/evidence-based care’ were eventually found to be. As a meme, it’s turning out to have the life of a fruit fly.
- It has to be easy to access, preferably on something the average patient or clinician already has or can acquire easily, like a laptop, tablet or smartphone. The idea of having to place a special purpose-built device in, let’s say, a home, is looking more and more ‘analogue’ indeed, a trend we are seeing in the traditional hub-based telehealth market and even slowly in telecare and traditional PERS.
- Funding models are changing, with more bootstrapping, self-funding, expand you go and less emphasis on big investment and selling out fast. As funders on a NYeC DHC panel pointed out last Wednesday, don’t raise more – or less – than you need.
At #MedMo16, Crowd Challenge participants were judged by a combination of the interested MedStartr/Health 2.0 NYC community through the MedStartr funding platform, and then by a panel of judges who have leading clinical, technological, patient advocate and funding experience. In short, a group that has seen a lot over the past decade plus, has been up and down the Hype Cycle, and is down to Brass Tacks.
The innovations that bubbled up through the finalists (more…)
Again courtesy of the MedStartr crowd-based healthcare investment fund and HealthTechTalkLive is the video of the second day at #MedMo16 from City Winery in NYC. It is just over 6 hours and includes both a panel discussion and individual presentations on what healthcare and the ACA will look in the Trump administration, blockchain, what it is like to grow your startup to a ‘baby unicorn’, human-centered design, investment and–most interesting to this marketer–being a ‘lean rat’ to run that business plan maze (2:29:00).
The five winners of the Mega Challenge start at 5:55:00:
Population Health, Payers and PharmaTech: EllieGrid (med management) and Mymee (personal health coach)
People’s Choice: Aloha Health (personalized care data for engagement)
Devices and Wearable Health Tech: Ceeable (cloud-based eye exam)
Clinical Innovations and Hospital Tech: Haystack (proteome molecular profiling for cancer)
Day 2 link is here. More on this when your Editor has time to recover! Special thanks to Alex Fair, Tom Tagariello, Ben Chodor, Ivan Schlachter, Mimi Rosenfeld and Steve Greene on the #MedMo16 team.